67 related articles for article (PubMed ID: 12181931)
21. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
22. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
23. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
24. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a.
Liscić RM; Brecelj J
Croat Med J; 2004 Jun; 45(3):323-7. PubMed ID: 15185427
[TBL] [Abstract][Full Text] [Related]
25. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
26. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
[TBL] [Abstract][Full Text] [Related]
27. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
[TBL] [Abstract][Full Text] [Related]
28. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
29. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
[TBL] [Abstract][Full Text] [Related]
30. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
31. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Webb UH
J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
[TBL] [Abstract][Full Text] [Related]
32. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
33. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
[TBL] [Abstract][Full Text] [Related]
34. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
35. Interferons in relapsing remitting multiple sclerosis.
Rudick RA; Cookfair DL; Griffin J; Hauser S; Piantadosi S
Lancet; 2003 May; 361(9371):1824; author reply 1824-5. PubMed ID: 12781561
[No Abstract] [Full Text] [Related]
36. Interferons in relapsing remitting multiple sclerosis.
Freedman M; King J; Oger J; Sharief M; Hartung HP;
Lancet; 2003 May; 361(9371):1822-3; author reply 1823-4. PubMed ID: 12781558
[No Abstract] [Full Text] [Related]
37. Interferons in relapsing remitting multiple sclerosis.
Goodin DS
Lancet; 2003 May; 361(9371):1821; author reply 1823-4. PubMed ID: 12781556
[No Abstract] [Full Text] [Related]
38. Interferons in relapsing remitting multiple sclerosis.
Kappos L; Kesselring J
Lancet; 2003 May; 361(9371):1821-2; author reply 1823-4. PubMed ID: 12781557
[No Abstract] [Full Text] [Related]
39. Interferons in relapsing remitting multiple sclerosis.
Kolar OJ; Bauerle JA; Lee H
Lancet; 2003 May; 361(9371):1825. PubMed ID: 12781563
[No Abstract] [Full Text] [Related]
40. Interferons in relapsing remitting multiple sclerosis.
Paty D; Arnason B; Li D; Traboulsee A
Lancet; 2003 May; 361(9371):1822; author reply 1823-4. PubMed ID: 12781559
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
